

Cite as: M. J. Lajoie *et al.*, *Science*  
10.1126/science.aba6527 (2020).

# Designed protein logic to target cells with precise combinations of surface antigens

**Marc J. Lajoie<sup>1,2\*</sup>†‡, Scott E. Boyken<sup>1,2\*</sup>†, Alexander I. Salter<sup>3,4\*</sup>, Jilliane Bruffey<sup>1,2,5</sup>, Anusha Rajan<sup>3,4</sup>, Robert A. Langan<sup>1,2</sup>†‡, Audrey Olshefsky<sup>1,6</sup>, Vishaka Muhunthan<sup>3,4</sup>, Matthew J. Bick<sup>1,2</sup>†‡, Mesfin Gewe<sup>4</sup>, Alfredo Quijano-Rubio<sup>1,2,6</sup>, JayLee Johnson<sup>1</sup>, Garreck Lenz<sup>1</sup>, Alisha Nguyen<sup>1</sup>, Suzie Pun<sup>6,7</sup>, Colin E. Correnti<sup>4</sup>, Stanley R. Riddell<sup>3,4,8</sup>, David Baker<sup>1,2,9</sup>†**

<sup>1</sup>Institute for Protein Design, University of Washington, Seattle, WA, USA. <sup>2</sup>Department of Biochemistry, University of Washington, Seattle, WA, USA. <sup>3</sup>Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. <sup>4</sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. <sup>5</sup>Graduate Program in Molecular and Cellular Biology, University of Washington, Seattle, WA, USA. <sup>6</sup>Department of Bioengineering, University of Washington, Seattle, WA, USA. <sup>7</sup>Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA, USA. <sup>8</sup>Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA. <sup>9</sup>Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.

\*These authors contributed equally to this work.

†Corresponding author. Email: mlajoie@lyell.com (M.J.L.); dabaker@uw.edu (D.B.)

‡Present address: Lyell Immunopharma, Inc., Seattle, WA, USA.

**Precise cell targeting is challenging because most mammalian cell types lack a single surface marker that distinguishes them from other cells. A solution would be to target cells based on specific combinations of proteins present on their surfaces. We design colocalization-dependent protein switches (Co-LOCKR) that perform AND, OR, and NOT Boolean logic operations. These switches activate through a conformational change only when all conditions are met, generating rapid, transcription-independent responses at single-cell resolution within complex cell populations. We implement AND gates to redirect T cell specificity against tumor cells expressing two surface antigens while avoiding off-target recognition of single-antigen cells, and 3-input switches that add NOT or OR logic to avoid or include cells expressing a third antigen. Thus, de novo designed proteins can perform computations on the surface of cells, integrating multiple distinct binding interactions into a single output.**

Biological systems are complex; therefore, interventions that perturb these systems must achieve specific targeting in mixed populations of closely related cells. Cells displaying a unique surface marker can be targeted with antibodies, but a single marker is rarely sufficient to identify specific cell types. Bispecific antibodies can achieve some selectivity by simultaneously engaging two targets (1, 2), but this strategy requires delicate tuning of the individual binding affinities to reduce interactions with cells expressing just one of the targets. A generalized approach for distinguishing cells based on combinations of surface markers is needed. Toward this end, we sought to develop a modular protein system capable of taking multiple binding events as input, computing combinations of Boolean logic operations (AND, OR, and NOT) without requiring cellular machinery for signal integration, and producing a single output (Fig. 1A).

How does one design a system that activates only on the surface of a cell and not in solution? Given that antigen binding at the cell surface increases the local concentration of the bound protein, such a system potentially could be constructed from an actuator that responds to proximity. The actuation must be modular and independent of target antigen

identity to be generally useful. We began from de novo designed protein switches that activate in solution: Latching Orthogonal Cage–Key protein (LOCKR) (3) switches consist of a structural “Cage” protein that uses a “Latch” domain to sequester a functional peptide in an inactive conformation until binding of a separate “Key” protein induces a conformational change that permits binding to an “Effector” protein. Cage, Key, and Effector bind in a three-way equilibrium, and the sensitivity of the switch can be tuned by adjusting the relative Cage–Latch and Cage–Key affinities. Previous LOCKR switches functioned in the yeast cytoplasm (3), but were aggregation-prone once purified, likely due to domain swapping of interchangeable symmetric repeats present in the parental homotrimer of  $\alpha$ -helical hairpins (4). To alleviate aggregation, we used Rosetta (5) to design a new LOCKR switch with shorter helices, improved hydrophobic packing, and an additional hydrogen bond network to promote interaction specificity among the helices (fig. S1, A to D, computational protein design section of the supplementary materials). The new design was nearly 100% monomeric (fig. S2, top), and a 2.1 Å x-ray crystal structure (PDB ID: 7JH5) closely matched the design model (Fig. 1B and table S1) with

1.1 Å root mean squared deviation (RMSD) across all backbone atoms and 0.5 Å RMSD across all sidechain heavy atoms in the newly designed hydrogen bond network (Fig. 1B).

To install an output function into Co-LOCKR, we chose the Bim-Bcl2 pair as a model system (6). Bim was encoded into the Latch as a sequestered peptide; Bcl2 was used as the Effector. We added targeting domains that recruit the Co-LOCKR Cage and Key to cells expressing target antigens. While the targeting domains should bind to any cell expressing their target antigens, only cells with both antigens should colocalize Cage and Key (Fig. 1, C to F). Because Co-LOCKR is thermodynamically controlled, complex formation occurs at much lower concentrations when the components are co-localized on a surface than when they are free in solution (fig. S3, A and B); colocalization shifts the binding equilibrium in favor of complex formation (fig. S3C).

To evaluate the ability of Co-LOCKR to target cells co-expressing a precise combination of surface antigens, we developed a mixed population flow cytometry assay by combining four K562 cell lines expressing Her2-eGFP, EGFR-iRFP, both, or neither (Fig. 1D). We used Designed Ankyrin Repeat Protein (DARPin) domains (7, 8) to target the Cage and Key to Her2 and EGFR, respectively. If the system functions as designed, only cells co-expressing both Her2 and EGFR should activate Co-LOCKR and bind Bcl2: the Cage contains the sequestered Bim peptide and the Key is required for its exposure. We refer to this Co-LOCKR configuration as CL<sub>C<sub>H</sub>K<sub>E</sub></sub>; in this nomenclature “CL” refers to Co-LOCKR, C<sub>H</sub> indicates that the Cage is targeted to Her2, and K<sub>E</sub> indicates that the Key is targeted to EGFR (table S2). When the mixed population of cells was co-incubated with an equimolar dilution series of Cage and Key (3 μM to 1.4 nM) and washed before adding AlexaFluor594-labeled Bcl2 (Bcl2-AF594), the expected sigmoidal binding curve was observed for the Her2/EGFR cells but not for cells expressing either antigen alone (Fig. 1G).

We next sought to tune the dynamic range of Co-LOCKR activation to increase colocalization-dependent activation sensitivity and responsiveness. The sensitivity of previous LOCKR switches was tuned by shortening the Latch to produce a “toehold” which allows the key to outcompete the latch (3), but this also promoted aggregation (fig. S2, bottom). We therefore focused on designing mutations rather than toeholds to tune the relative interaction affinities of the Co-LOCKR system to be colocalization-dependent (fig. S4, A to C). We mutated large, hydrophobic residues in the Latch (I287A, I287S, I269S) or Cage (L209A) to weaken Cage-Latch affinity (Fig. 2A). Biolayer interferometry indicated that increasingly disruptive mutations improved responsiveness (fig. S5, A and B), and flow cytometry showed that tuning the Cage-Latch interface enhanced colocalization-dependent signal without compromising specificity (Fig. 2B and fig. S5C).

Colocalization-dependent activation occurred even at low nanomolar concentrations of CL<sub>C<sub>H</sub>K<sub>E</sub></sub> (fig. S5, D and E). Very little Effector binding was observed for cells expressing Her2 or EGFR alone, confirming that Co-LOCKR has single-cell targeting resolution in a mixed population. Of the switches tested, I269S exhibited the greatest activation (fig. S6A), the parental Co-LOCKR design exhibited the lowest off-target activation (fig. S6B), and I287A exhibited the highest specificity (on-target signal divided by max off-target signal, fig. S6C).

Co-localization dependent activation was observed further at the sub-cellular level by confocal microscopy. CL<sub>C<sub>H</sub>K<sub>E</sub></sub> recruited Bcl2-AF680 to the plasma membrane of HEK293T/Her2/EGFR cells but not HEK293T/Her2 or HEK293T/EGFR (Fig. 2C). There was a close correspondence between regions of the plasma membrane exhibiting colocalized Her2-eGFP and EGFR-iRFP signal and Co-LOCKR activation (Fig. 2D).

To assess the flexibility of Co-LOCKR, we attempted to specifically target alternative pairwise combinations of three cancer-associated antigens (Her2, EGFR, and EpCAM). Each of these antigens are expressed at differing levels by engineered K562 cell lines or human cancer cell lines (figs. S7A and S8A and table S3). Using the I269S variant to maximize detection of low levels of antigen, (i) Co-LOCKR distinguished the correct pair of antigens in every case, and (ii) the magnitude of Bcl2 binding corresponded with the expression level of the lower-expressed of the two target antigens (Fig. 3A and fig. S8, B and C), consistent with a stoichiometric binding mechanism for colocalization-dependent activation. Taken together, these results demonstrate the modularity of Co-LOCKR to target several antigens expressed at differing levels. While we chose DARPins as targeting domains to allow facile expression of Co-LOCKR variants, single chain variable fragments can also be used (fig. S9).

The colocalization-dependent activation mechanism of Co-LOCKR can in principle be extended to include OR logic by adding a second Key fused to a targeting domain against an alternative surface marker (Fig. 3B) and NOT logic by adding a Decoy protein fused to a targeting domain against a surface marker to be avoided; the Decoy acts as a sponge to sequester the Key, thereby preventing Cage activation (Fig. 3D). Using Her2, EGFR, and EpCAM as model antigens (Ag), we first explored [*Ag<sub>1</sub> AND either Ag<sub>2</sub> OR Ag<sub>3</sub>*] logic on the surface of cells (Fig. 3B). To assess the programmability of Co-LOCKR targeting, we tested all three combinations: [*Her2 AND either EGFR OR EpCAM*], [*EGFR AND either Her2 OR EpCAM*], and [*EpCAM AND either Her2 OR EGFR*]. In all cases, the correct cell sub-population was targeted at levels consistent with the limiting target antigen (Fig. 3C). For example, CL<sub>C<sub>E</sub>K<sub>H</sub>K<sub>Ep</sub></sub> targeted cells expressing EGFR/EpCAM<sup>lo</sup> 10-fold over background, Her2/EGFR/EpCAM<sup>o</sup> 59-fold over background, and Her2/EGFR/EpCAM<sup>hi</sup> 56-fold above

background, but exhibited minimal off-target activation on cells missing at least one antigen (Fig. 3C, middle panel).

We next explored  $[Ag_1 \text{ AND } Ag_2 \text{ NOT } Ag_3]$  logic using CL<sub>C<sub>H</sub>K<sub>Ep</sub>D<sub>E</sub></sub> (D for Decoy) and the same set of model antigens (Fig. 3D). We tuned the Decoy-Key affinity with designed point mutations to maximize the abrogation of activation when the Decoy is targeted, and to minimize the interference of the decoy with activation when it is not targeted (fig. S10). Recruitment of Decoy reduced activation to near background levels on cells with  $Ag_3$  on their surface, while reducing activation on cells lacking  $Ag_3$  by only 15% (Fig. 3E). Consistent with the stoichiometric sequestration mechanism,  $Ag_3$  must be expressed at higher levels than  $Ag_2$  so that the Decoy can sequester all molecules of the Key (Fig. 3D). While bispecific antibodies can be made to approximate  $[Ag_1 \text{ AND } Ag_2]$  logic by tuning binding affinity, we are not aware of any current approach which can achieve the precise  $[Ag_1 \text{ AND } Ag_2 \text{ NOT } Ag_3]$  logic of Fig. 3E and fig. S11.

As a first step toward a real-world application, we explored the retargeting of primary human T cell effector function against tumor cells in vitro. We designed a Bcl2 CAR that targets Bim peptides displayed on the surface of a target cell; the CAR contains a stabilized variant of human Bcl2, a flexible extracellular spacer domain (9), CD28/CD3 $\zeta$  signaling domains, and a truncated EGFR (EGFRt) selection marker (10) linked by a T2A ribosomal skipping sequence (fig. S12A). The Bcl2 CAR functions as designed: purified CD8<sup>+</sup>EGFRt<sup>+</sup> Bcl2 CAR T cells efficiently recognized K562 cells stably expressing a surface-exposed Bim-GFP fusion protein (fig. S12, B and C).

With Bcl2 CAR T cells in hand, we investigated whether the Co-LOCKR proteins could mediate T cell activation by Raji and K562 cells expressing combinations of Her2, EGFR, and EpCAM. The Raji cells expressed lower levels of transduced antigens than did the K562 cell lines (fig. S7, A and B, and table S3), and hence more stringently test Co-LOCKR sensitivity, whereas the K562 cells better assess specificity. CL<sub>C<sub>H</sub>K<sub>Ep</sub></sub> and CL<sub>C<sub>Ep</sub>K<sub>H</sub></sub> (using the parental unmutated Cage) promoted IFN- $\gamma$  release only when co-cultured with Raji/EpCAM/Her2 cells and not Raji/EpCAM or Raji/Her2 (fig. S12D). Titration experiments showed that CAR T effector function could be specifically targeted using between 2.5 nM to 20 nM of Co-LOCKR without causing unintended activation by off-target cells (fig. S13); still lower concentrations would likely be effective using higher affinity binding domains.

Next, we assessed the ability of Co-LOCKR to direct CAR T cell cytotoxicity against specific subsets of cells within a mixed population. Raji, Raji/EpCAM, Raji/Her2, and Raji/EpCAM/Her2 were differentially labeled with fluorescent Cell Trace dyes, mixed together with CAR T cells and CL<sub>C<sub>H</sub>K<sub>Ep</sub></sub> (fig. S12F), and killing of each of the cell lines was assessed using flow cytometry. After 48 hours, Raji/EpCAM/Her2 cells

were preferentially killed, but a fraction of Raji/EpCAM cells were also targeted (fig. S12G), suggesting that even the parental Cage and Key were too leaky for CAR T cell recruitment. We overcame this basal activation by modifying the length of the Key (fig. S12E): the combination of parental Cage and  $\Delta$ N3 Key (three N-terminal amino acids deleted) selectively targeted Raji/EpCAM/Her2 cells and mitigated unintended killing of Raji/EpCAM and Raji/Her2 cells (fig. S12, F and G). A Chromium release assay showed that CL<sub>C<sub>H</sub>K<sub>Ep</sub></sub> targeted only Raji/EpCAM/Her2 cells and initiated rapid cell killing within 4 hours (fig. S12H). Thus, Co-LOCKR can be used to restrict IFN- $\gamma$  release and cell killing to only those tumor cells that express a specific pair of antigens.

We next evaluated Co-LOCKR AND logic for additional tumor antigen pairs ( $[Her2 \text{ AND } EpCAM]$ ,  $[Her2 \text{ AND } EGFR]$ ) and varying antigen density profiles using K562 cell lines (fig. S7A and table S3) and solid tumor lines (fig. S8A). Raji cells with low antigen density yielded modest IFN- $\gamma$  (fig. S14A), K562/Her2/EpCAM<sup>lo</sup> and SKBR3 breast cancer cells yielded intermediate IFN- $\gamma$  (Fig. 4A and fig. S14B), and both K562/Her2/EpCAM<sup>hi</sup> and K562/Her2/EGFR cells yielded high IFN- $\gamma$  release for their respective Co-LOCKRs (Fig. 4A and fig. S14C). CL<sub>C<sub>Ep</sub>K<sub>H</sub></sub> induced IFN- $\gamma$  release in response to Raji/Her2/EpCAM 3.9-fold above background, SKBR3 4.8-fold above background, K562/Her2/EpCAM<sup>lo</sup> 16-fold above background, and K562/Her2/EpCAM<sup>hi</sup> 51-fold above background, with minimal off-target cytokine release. IFN- $\gamma$  production did not increase appreciably when the target cells expressed high levels of a single antigen. CAR T cells proliferated only upon co-culture with target cells co-expressing the correct pair of antigens, and the degree of proliferation positively correlated with antigen density (Fig. 4B and fig. S14D). The flow cytometry-based killing assay confirmed AND gate selective cytotoxicity with both CL<sub>C<sub>H</sub>K<sub>Ep</sub></sub> and CL<sub>C<sub>Ep</sub>K<sub>H</sub></sub> against Raji/EpCAM/Her2 without depleting single antigen-positive cells (Fig. 4C). A similar result was observed for both CL<sub>C<sub>H</sub>K<sub>E</sub></sub> and CL<sub>C<sub>E</sub>K<sub>H</sub></sub> against Raji/Her2/EGFR (fig. S14E), although killing was less effective, likely due to the lower expression levels of EGFR compared to EpCAM in Raji/Her2/EGFR and Raji/EpCAM/Her2, respectively. We also did not observe fratricide of the EGFRt<sup>+</sup> CAR T cells used in the experiment, which could have been targeted by the anti-EGFR DARPIn targeting domain of CL<sub>C<sub>H</sub>K<sub>E</sub></sub> or CL<sub>C<sub>E</sub>K<sub>H</sub></sub> (fig. S14F).

Encouraged by robust AND logic, we evaluated more complex operations involving combinations of AND and either OR or NOT logic. CAR T cells co-cultured with AND/OR Co-LOCKRs (CL<sub>C<sub>H</sub>K<sub>E</sub>K<sub>Ep</sub></sub>, CL<sub>C<sub>E</sub>K<sub>H</sub>K<sub>Ep</sub></sub>, and CL<sub>C<sub>Ep</sub>K<sub>H</sub>K<sub>E</sub></sub>) each carried out  $[Ag_1 \text{ AND } \textit{either } Ag_2 \text{ OR } Ag_3]$  logic with respect to IFN- $\gamma$  production (Fig. 4D and fig. S14G) and proliferation (Fig. 4E) against K562 cell lines, as well as selective killing in a mixed population of Raji cell lines (Fig. 4F and fig. S14H).

CAR T cells co-cultured with an AND/NOT Co-LOCKR ( $CL_{C_H}K_{E_P}D_E$ ) carried out [*Her2 AND EpCAM NOT EGFR*] logic: IFN- $\gamma$  production and proliferation were induced in the presence of K562/Her2/EpCAM<sup>lo</sup> but not K562/EGFR/Her2/EpCAM<sup>lo</sup> cells (Fig. 4, G and H). Consistent with the observations above,  $Ag_3$  in the NOT operation had to be expressed at higher levels than  $Ag_2$  (Fig. 4, G to I, and fig. S15, A to C). While these data indicate that careful antigen selection and some tuning are necessary for robust control of logical operations, the ability of  $CL_{C_H}K_{E_P}D_E$  to direct CAR T cell mediated killing of Her2/EpCAM cells but not Her2/EpCAM/EGFR cells (Fig. 4I, right-hand panel) further highlights the power of Co-LOCKR to perform [*Ag<sub>1</sub> AND Ag<sub>2</sub> NOT Ag<sub>3</sub>*] logic for specific cell targeting.

Two previous strategies improved the specificity of CAR T cells by approximating AND logic. First, Kloss *et al.* (11) directly modulated signaling from a sub-optimally-activating first generation CAR (CD3 $\zeta$  only) using a chimeric costimulatory receptor (CCR, costimulatory domain only) that recognizes a distinct second antigen. Although T cell activation is reduced in the absence of the second antigen, targeting remains leaky because the CAR T cells can lyse both tumor and normal cells expressing the antigen targeted by the CD3 $\zeta$  CAR, even when the CCR is not engaged. Second, Morsut *et al.* (12) developed synthetic Notch receptors that modularly induce expression of effector proteins in engineered cells. Roybal *et al.* (13) applied this technology to enhance CAR T cell specificity using a synthetic Notch receptor that recognizes one antigen to induce expression of a CAR recognizing a second antigen. While this “If-Then” logic strategy has shown promise in pre-clinical models in which the target antigens exist distally, the CAR will kill any nearby cell expressing the target antigen, so off-tumor toxicity can occur when the Notch receptor and CAR targets are expressed in neighboring healthy tissues (14). Co-LOCKR has potential advantages over these approaches as activation requires binding in cis to a precise combination of target antigens before recruiting the cognate CAR T cells, and thus it can direct killing without harming neighboring off-target cells displaying single antigens (Fig. 4, C, F, and I). OR (15, 16) and NOT (15, 17) logic have also been described for CAR T cells, but not in combination with AND logic as we describe here.

Our CAR T cell experiments demonstrate the potential for Co-LOCKR to mediate targeting specificity in vitro; however, several additional challenges will have to be met for Co-LOCKR to be a clinically translatable therapeutic. In vivo studies will be needed to assess and improve the pharmacokinetics of the Co-LOCKR components. Immunogenicity of the designed proteins is also a potential concern, similar to any other system comprising non-human proteins. As Co-LOCKR actuation is thermodynamically controlled, the therapeutic index will depend on the affinity of the targeting

domains used to direct the Co-LOCKR proteins to antigens on the target cells: if the affinities are sub-nanomolar, dosing can be far below the 40 nM level where activation starts to occur in solution (fig. S13). CAR T efficacy could also be improved by optimizing the CAR, for example by using alternative signaling molecules (18–20).

The power of Co-LOCKR results from the integration of multiple coherent or competing inputs that determine the magnitude of a single response. The output signal—exposure of the functional peptide on the Latch—is increased by Key binding and countered by Decoy competition. Thus, the proteins can intrinsically perform logic rather than relying on cellular machinery for signal integration. Although our present work has focused on development of the Co-LOCKR system and CAR T cell applications, the Co-LOCKR system should be powerful for engineering biology in any setting that requires proximity-based activation or targeting of specific sub-populations of cells.

## REFERENCES AND NOTES

1. C. Sellmann, A. Doerner, C. Knuehl, N. Rasche, V. Sood, S. Krah, L. Rhiel, A. Messemer, J. Wesolowski, M. Schuette, S. Becker, L. Toleikis, H. Kolmar, B. Hock, Balancing selectivity and efficacy of bispecific epidermal growth factor receptor (EGFR)  $\times$  c-MET antibodies and antibody-drug conjugates. *J. Biol. Chem.* **291**, 25106–25119 (2016). [doi:10.1074/jbc.M116.753491](https://doi.org/10.1074/jbc.M116.753491) [Medline](#)
2. Y. Mazor, K. F. Sachsenmeier, C. Yang, A. Hansen, J. Filderman, K. Mulgrew, H. Wu, W. F. Dall'Acqua, Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. *Sci. Rep.* **7**, 40098 (2017). [doi:10.1038/srep40098](https://doi.org/10.1038/srep40098) [Medline](#)
3. R. A. Langan, S. E. Boyken, A. H. Ng, J. A. Samson, G. Dods, A. M. Westbrook, T. H. Nguyen, M. J. Lajoie, Z. Chen, S. Berger, V. K. Mulligan, J. E. Dueber, W. R. P. Novak, H. El-Samad, D. Baker, De novo design of bioactive protein switches. *Nature* **572**, 205–210 (2019). [doi:10.1038/s41586-019-1432-8](https://doi.org/10.1038/s41586-019-1432-8) [Medline](#)
4. S. E. Boyken, Z. Chen, B. Groves, R. A. Langan, G. Oberdorfer, A. Ford, J. M. Gilmore, C. Xu, F. DiMaio, J. H. Pereira, B. Sankaran, G. Seelig, P. H. Zwart, D. Baker, De novo design of protein homo-oligomers with modular hydrogen-bond network-mediated specificity. *Science* **352**, 680–687 (2016). [doi:10.1126/science.aad8865](https://doi.org/10.1126/science.aad8865) [Medline](#)
5. A. Leaver-Fay, M. Tyka, S. M. Lewis, O. F. Lange, J. Thompson, R. Jacak, K. Kaufman, P. D. Renfrew, C. A. Smith, W. Sheffler, I. W. Davis, S. Cooper, A. Treuille, D. J. Mandell, F. Richter, Y.-E. A. Ban, S. J. Fleishman, J. E. Corn, D. E. Kim, S. Lyskov, M. Berrondo, S. Mentzer, Z. Popović, J. J. Havranek, J. Karanicolas, R. Das, J. Meiler, T. Kortemme, J. J. Gray, B. Kuhlman, D. Baker, P. Bradley, Rosetta3: An object-oriented software suite for the simulation and design of macromolecules. *Methods Enzymol.* **487**, 545–574 (2011). [doi:10.1016/B978-0-12-381270-4.00019-6](https://doi.org/10.1016/B978-0-12-381270-4.00019-6) [Medline](#)
6. L. Delgado-Soler, M. Pinto, K. Tanaka-Gil, J. Rubio-Martinez, Molecular determinants of Bim(BH3) peptide binding to pro-survival proteins. *J. Chem. Inf. Model.* **52**, 2107–2118 (2012). [doi:10.1021/ci3001666](https://doi.org/10.1021/ci3001666) [Medline](#)
7. C. Zahnd, E. Wyler, J. M. Schwenk, D. Steiner, M. C. Lawrence, N. M. McKern, F. Pecorari, C. W. Ward, T. O. Joos, A. Plückthun, A designed ankyrin repeat protein evolved to picomolar affinity to Her2. *J. Mol. Biol.* **369**, 1015–1028 (2007). [doi:10.1016/j.jmb.2007.03.028](https://doi.org/10.1016/j.jmb.2007.03.028) [Medline](#)
8. D. Steiner, P. Forrer, A. Plückthun, Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. *J. Mol. Biol.* **382**, 1211–1227 (2008). [doi:10.1016/j.jmb.2008.07.085](https://doi.org/10.1016/j.jmb.2008.07.085) [Medline](#)
9. M. Hudecek, D. Sommermeyer, P. L. Kosasih, A. Silva-Benedict, L. Liu, C. Rader, M. C. Jensen, S. R. Riddell, The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. *Cancer Immunol. Res.* **3**, 125–135 (2015). [doi:10.1158/2326-6066.CCR-14-0127](https://doi.org/10.1158/2326-6066.CCR-14-0127) [Medline](#)
10. X. Wang, W.-C. Chang, C. W. Wong, D. Colcher, M. Sherman, J. R. Ostberg, S. J.

- Forman, S. R. Riddell, M. C. Jensen, A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. *Blood* **118**, 1255–1263 (2011). [doi:10.1182/blood-2011-02-337360](https://doi.org/10.1182/blood-2011-02-337360) [Medline](#)
11. C. C. Kloss, M. Condomines, M. Cartellieri, M. Bachmann, M. Sadelain, Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. *Nat. Biotechnol.* **31**, 71–75 (2013). [doi:10.1038/nbt.2459](https://doi.org/10.1038/nbt.2459) [Medline](#)
  12. L. Morsut, K. T. Roybal, X. Xiong, R. M. Gordley, S. M. Coyle, M. Thomson, W. A. Lim, Engineering customized cell sensing and response behaviors using synthetic Notch receptors. *Cell* **164**, 780–791 (2016). [doi:10.1016/j.cell.2016.01.012](https://doi.org/10.1016/j.cell.2016.01.012) [Medline](#)
  13. K. T. Roybal, L. J. Rupp, L. Morsut, W. J. Walker, K. A. McNally, J. S. Park, W. A. Lim, Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. *Cell* **164**, 770–779 (2016). [doi:10.1016/j.cell.2016.01.011](https://doi.org/10.1016/j.cell.2016.01.011) [Medline](#)
  14. S. Srivastava, A. I. Salter, D. Liggitt, S. Yechan-Gunja, M. Sarvothama, K. Cooper, K. S. Smythe, J. A. Dudakov, R. H. Pierce, C. Rader, S. R. Riddell, Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. *Cancer Cell* **35**, 489–503.e8 (2019). [doi:10.1016/j.ccell.2019.02.003](https://doi.org/10.1016/j.ccell.2019.02.003) [Medline](#)
  15. J. H. Cho, J. J. Collins, W. W. Wong, Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. *Cell* **173**, 1426–1438.e11 (2018). [doi:10.1016/j.cell.2018.03.038](https://doi.org/10.1016/j.cell.2018.03.038) [Medline](#)
  16. E. Zah, M.-Y. Lin, A. Silva-Benedict, M. C. Jensen, Y. Y. Chen, T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. *Cancer Immunol. Res.* **4**, 498–508 (2016). [doi:10.1158/2326-6066.CIR-15-0231](https://doi.org/10.1158/2326-6066.CIR-15-0231) [Medline](#)
  17. V. D. Fedorov, M. Themeli, M. Sadelain, PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. *Sci. Transl. Med.* **5**, 215ra172 (2013). [doi:10.1126/scitranslmed.3006597](https://doi.org/10.1126/scitranslmed.3006597) [Medline](#)
  18. S. Tammana, X. Huang, M. Wong, M. C. Milone, L. Ma, B. L. Levine, C. H. June, J. E. Wagner, B. R. Blazar, X. Zhou, 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. *Hum. Gene Ther.* **21**, 75–86 (2010). [doi:10.1089/hum.2009.122](https://doi.org/10.1089/hum.2009.122) [Medline](#)
  19. Y. Kagoya, S. Tanaka, T. Guo, M. Anczurowski, C.-H. Wang, K. Saso, M. O. Butler, M. D. Minden, N. Hirano, A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. *Nat. Med.* **24**, 352–359 (2018). [doi:10.1038/nm.4478](https://doi.org/10.1038/nm.4478) [Medline](#)
  20. C. Sun, P. Shou, H. Du, K. Hirabayashi, Y. Chen, L. E. Herring, S. Ahn, Y. Xu, K. Suzuki, G. Li, O. Tshouridis, L. Su, B. Savoldo, G. Dotti, THEMIS-SHP1 recruitment by 4-1BB tunes LCK-mediated priming of chimeric antigen receptor-redirectioned T cells. *Cancer Cell* **37**, 216–225.e6 (2020). [doi:10.1016/j.ccell.2019.12.014](https://doi.org/10.1016/j.ccell.2019.12.014) [Medline](#)
  21. B. Kuhlman, D. Baker, Native protein sequences are close to optimal for their structures. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 10383–10388 (2000). [doi:10.1073/pnas.97.19.10383](https://doi.org/10.1073/pnas.97.19.10383) [Medline](#)
  22. S. J. Fleishman, A. Leaver-Fay, J. E. Corn, E.-M. Strauch, S. D. Khare, N. Koga, J. Ashworth, P. Murphy, F. Richter, G. Lemmon, J. Meiler, D. Baker, RosettaScripts: A scripting language interface to the Rosetta macromolecular modeling suite. *PLOS ONE* **6**, e20161 (2011). [doi:10.1371/journal.pone.0020161](https://doi.org/10.1371/journal.pone.0020161) [Medline](#)
  23. J. W. Checco, E. F. Lee, M. Evangelista, N. J. Sleebbs, K. Rogers, A. Pettikiriarachchi, N. J. Kershaw, G. A. Eddinger, D. G. Belair, J. L. Wilson, C. H. Eller, R. T. Raines, W. L. Murphy, B. J. Smith, S. H. Gellman, W. D. Fairlie,  $\alpha/\beta$ -Peptide foldamers targeting intracellular protein-protein interactions with activity in living cells. *J. Am. Chem. Soc.* **137**, 11365–11375 (2015). [doi:10.1021/jacs.5b05896](https://doi.org/10.1021/jacs.5b05896) [Medline](#)
  24. A. Goldenzweig, M. Goldsmith, S. E. Hill, O. Gertman, P. Laurino, Y. Ashani, O. Dym, T. Unger, S. Albeck, J. Prilusky, R. L. Lieberman, A. Aharoni, I. Silman, J. L. Sussman, D. S. Tawfik, S. J. Fleishman, Automated structure- and sequence-based design of proteins for high bacterial expression and stability. *Mol. Cell* **63**, 337–346 (2016). [doi:10.1016/j.molcel.2016.06.012](https://doi.org/10.1016/j.molcel.2016.06.012) [Medline](#)
  25. D. G. Gibson, H. O. Smith, C. A. Hutchison 3rd, J. C. Venter, C. Merryman, Chemical synthesis of the mouse mitochondrial genome. *Nat. Methods* **7**, 901–903 (2010). [doi:10.1038/nmeth.1515](https://doi.org/10.1038/nmeth.1515) [Medline](#)
  26. N. Stefan, P. Martin-Killias, S. Wyss-Stoeckle, A. Honegger, U. Zangemeister-Wittke, A. Plückthun, DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. *J. Mol. Biol.* **413**, 826–843 (2011). [doi:10.1016/j.jmb.2011.09.016](https://doi.org/10.1016/j.jmb.2011.09.016) [Medline](#)
  27. W. Kabsch, XDS. *Acta Crystallogr. D* **66**, 125–132 (2010). [doi:10.1107/S0907444909047337](https://doi.org/10.1107/S0907444909047337) [Medline](#)
  28. A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J. Read, Phaser crystallographic software. *J. Appl. Crystallogr.* **40**, 658–674 (2007). [doi:10.1107/S0021889807021206](https://doi.org/10.1107/S0021889807021206) [Medline](#)
  29. P. D. Adams, P. V. Afonine, G. Bunkóczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L.-W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger, P. H. Zwart, PHENIX: A comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D* **66**, 213–221 (2010). [doi:10.1107/S0907444909052925](https://doi.org/10.1107/S0907444909052925) [Medline](#)
  30. T. C. Terwilliger, R. W. Grosse-Kunstleve, P. V. Afonine, N. W. Moriarty, P. H. Zwart, L.-W. Hung, R. J. Read, P. D. Adams, Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. *Acta Crystallogr. D* **64**, 61–69 (2008). [doi:10.1107/S090744490705024X](https://doi.org/10.1107/S090744490705024X) [Medline](#)
  31. P. Emsley, K. Cowtan, Coot: Model-building tools for molecular graphics. *Acta Crystallogr. D* **60**, 2126–2132 (2004). [doi:10.1107/S0907444904019158](https://doi.org/10.1107/S0907444904019158) [Medline](#)
  32. I. W. Davis, A. Leaver-Fay, V. B. Chen, J. N. Block, G. J. Kapral, X. Wang, L. W. Murray, W. B. Arendall 3rd, J. Snoeyink, J. S. Richardson, D. C. Richardson, MolProbity: All-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res.* **35**, W375–W383 (2007). [doi:10.1093/nar/gkm216](https://doi.org/10.1093/nar/gkm216) [Medline](#)
  33. A. D. Bandaranayake, C. Correnti, B. Y. Ryu, M. Brault, R. K. Strong, D. J. Rawlings, Daedalus: A robust, turnkey platform for rapid production of decigram quantities of active recombinant proteins in human cell lines using novel lentiviral vectors. *Nucleic Acids Res.* **39**, e143–e143 (2011). [doi:10.1093/nar/gkr706](https://doi.org/10.1093/nar/gkr706) [Medline](#)

#### ACKNOWLEDGMENTS

We would like to thank Andy Scharenberg, Wendell Lim, Rick Klausner, Lance Stewart, Anindya Roy, Zibo Chen, Adrian Briggs, Elizabeth Gray, Daniel Stetson, Marion Pepper, Lauren Carter, Brian Weitzner, Jocelynn Pearl, Howell Moffett, Ian Haydon, Daniel Campbell, Stephen Hauschka, Neil King, and Jesse Zalatan for helpful advice; Donna Prunkard and Han Nguyen for technical assistance with flow cytometry and cell sorting; Alex Kang for setting up crystal trays and looping crystals; Rashmi Ravichandran for protein purification; Stephanie Berger for sharing biotinylated Bcl2, David Hockenbery for sharing SKBR3 cells, and Didier Trono for sharing lentiviral packaging plasmids. We also thank the W.M. Keck Center for Advanced Studies in Neural Signaling (NIH grant S10 OD016240) and the helpful input of Nathaniel Peters and Gary Liu for confocal microscopy experiments. **Funding:** This work was supported by the HHMI (D.B.), the Open Philanthropy Project (D.B.), the NSF (D.B., CHE-1629214), the DTRA (D.B., HDTRA1-18-1-0001), the Nordstrom Barrier IPD Directors Fund (D.B.), the Washington Research Foundation and Translational Research Fund (D.B.), the Audacious Project organized by TED (D.B.), and the NIH (S.R.R., R01 CA114536; J.B., NIGMS T32GM008268). M.J.L. was supported by a Washington Research Foundation Innovation Postdoctoral Fellowship and a Cancer Research Institute Irvington Fellowship from the Cancer Research Institute. S.E.B. was supported by the Burroughs Wellcome Fund Career Award at the Scientific Interface. A.I.S. was supported by the FHCRC interdisciplinary training grant in cancer research and Hearst Foundation. A.O. was supported by NIH NCI grants 1R21CA232430-01 and T32CA080416. **Author contributions:** Marc Lajoie, Scott Boyken, Alexander Salter: Conceptualization, Methodology, Investigation, Software, Data analysis, Writing – original draft, Writing – review and editing, Visualization, Supervision. Jilliane Bruffey: Investigation, Data analysis, Writing – original draft, Writing – review and editing, Visualization. Anusha Rajan: Investigation. Robert Langan: Investigation, Software. Audrey Olshefsky: Methodology, Investigation, Software, Data analysis, Visualization. Vishaka Mhunthan: Investigation. Matthew Bick: Investigation, Software, Data analysis. Mesfin Gewe, Alfredo Quijano-Rubio, JayLee Johnson, Garreck Lenz, Alisha Nguyen: Investigation. Suzie Pun, Colin Correnti, Stanley Riddell: Supervision. David Baker: Conceptualization, Writing – original draft, Writing – review and editing, Visualization, Supervision. M.J.L., S.E.B., and D.B. conceived of the study. M.J.L., S.E.B., A.I.S., J.B., and A.O. designed the experiments. M.J.L., S.E.B., and R.A.L. designed the LOCKR proteins. M.J.L., A.I.S., A.R., and M.G. made the target cell lines. M.J.L., S.E.B., J.B., R.A.L., A.Q.R., J.J., G.L., and A.N. performed cloning.

protein expression, and biochemical characterization experiments. S.E.B. and M.J.B. solved the crystal structure. M.J.L., J.B., and A.O. quantified co-LOCKR activation using flow cytometry. A.O. performed the microscopy experiment and data analysis. A.I.S., A.R., and V.M. performed the T cell experiments. M.J.L., S.E.B., A.I.S., J.B., R.A.L., A.O., and M.J.B. analyzed the data. M.J.L., S.E.B., A.I.S., S.P., C.E.C., S.R.R., and D.B. supervised the study. M.J.L., S.E.B., A.I.S., and D.B. wrote the manuscript. All authors reviewed the manuscript and provided feedback. **Competing interests:** M.J.L., S.E.B., A.I.S., J.B., R.A.L., M.G., C.E.C., S.R.R., and D.B. are inventors on patents related to this work. M.J.L., S.E.B., A.I.S., R.A.L., M.J.B., S.R.R., and D.B. hold equity in Lyell Immunopharma. D.B. holds equity in Sana Biotechnology. M.J.L., S.E.B., R.A.L., M.J.B., and S.R.R. are employees of Lyell Immunopharma. A.I.S. is a consultant of Lyell Immunopharma. **Data and materials availability:** Coordinates and structure files have been deposited to the Protein Data Bank (PDB) with accession code 7JH5. The python script used to analyze confocal microscopy images is included in the supplemental material. Expression plasmids and cell lines are available upon request. Primary T cells are not available.

## SUPPLEMENTARY MATERIALS

[science.sciencemag.org/cgi/content/full/science.aba6527/DC1](http://science.sciencemag.org/cgi/content/full/science.aba6527/DC1)

Materials and Methods

Figs. S1 to S21

Tables S1 to S5

Supplementary Scripts


References (21–33)

MDAR Reproducibility Checklist


20 December 2019; accepted 28 July 2020

Published online 20 August 2020


10.1126/science.aba6527




**Fig. 1. A de novo designed protein switch performs AND logic on the cell surface.** (A) The ability to compute logic operations on the surface of cells could increase targeting selectivity, provide flexibility for heterogeneous tissue, and avoid healthy tissue. (B) Structure of Cage design used to create Co-LOCKR; the x-ray crystal structure (white, PDB ID: 7JH5) matches the computational design model (green) with 1.1 Å RMSD across all backbone atoms. Cross-sections illustrate asymmetric packing of hydrophobic residues (red square) and an asymmetric hydrogen bond network (blue square). (C) Colocalization-dependent protein switches are tuned so that Cage and Key do not interact in solution but strongly interact when colocalized on a surface via targeting domains. (D) Flow cytometry discriminates Her2<sup>+</sup>/EGFR<sup>+</sup> cells in a mixed population of K562 cells expressing Her2-eGFP, EGFR-iRFP, both, or neither. (E) An Effector protein is recruited only when Cage and Key are colocalized on the surface of the same cell (AND logic). (F) The mixed population of cells from Fig. 1D was incubated with 111 nM Her2-targeted Cage, 111 nM EGFR-targeted Key, and 50 nM Bcl2-AF594. Bcl2 binding was only observed for the K562/Her2/EGFR cells. (G) The mixed population of cells from Fig. 1D was incubated with a dilution series of Her2-targeted Cage and EGFR-targeted Key, washed, and then incubated with 50 nM Bcl2-AF594. Bcl2 binding is reported relative to K562 cells incubated with 3000 nM Her2-targeted Cage, 3000 nM EGFR-targeted Key, and 50 nM Bcl2-AF594.



**Fig. 2. Tuning Co-LOCKR sensitivity.** (A) Design model of Co-LOCKR with the Bim functional peptide in yellow. Three buried hydrophobic amino acids were mutated to Ala or Ser to weaken the Cage–Latch affinity, thereby favoring Cage–Key binding. (B) Tuned Co-LOCKR variants exhibit greater colocalization-dependent activation than the unmutated parental variant. CL<sub>C<sub>H</sub>K<sub>E</sub></sub> variants recruiting Bcl2-AF594 were evaluated by flow cytometry using the mixed population of cells from Fig. 1D. The data shown represent 12.3 nM CL<sub>C<sub>H</sub>K<sub>E</sub></sub> (*n* = 1), and fig. S5C shows the complete dilution series for each variant. (C) Confocal microscopy of HEK293T cell lines shows that Co-LOCKR switches recruit Bcl2-AF680 Effector proteins only where Her2 and EGFR are colocalized. Each cell line was incubated with CL<sub>C<sub>H</sub>K<sub>E</sub></sub> (I269S Cage) and Bcl2-AF680 before imaging. NucBlue is a nuclear stain, eGFP indicates Her2 localization, mCherry indicates EGFR localization, AF680 indicates Bcl2 binding in response to Co-LOCKR activation, and white indicates the intersection of Her2-eGFP and EGFR-mCherry signal. Scale bars are 10 μm. Uncropped versions of these images are included in fig. S16, A to C. (D) Heat map showing the intensity of AF680 signal (Co-LOCKR activation) versus eGFP (Her2) and mCherry (EGFR) pixel intensity. Calculations were based on the uncropped 293T/Her2/EGFR image in fig. S16A.



**Fig. 3. Co-LOCKR performs 2- and 3-input logic operations in mixed cell populations.** (A) Co-LOCKR was used to recruit Bcl2-AF594 for two populations of K562 cells expressing different combinations of Her2, EGFR, and EpCAM. Marker expression for each cell line and identity of the Cage and Key targeting domains are indicated below each bar plot. Red highlighting indicates the expected magnitude of Bcl2-AF594 signal based on relative antigen expression. (B) Schematic of  $[Her2 \text{ AND } \textit{either EGFR OR EpCAM}]$  logic mechanism. (C)  $[Ag_1 \text{ AND } \textit{either Ag}_2 \text{ OR Ag}_3]$  logic combinations were used to recruit Bcl2-AF594. (D) Schematic of  $[Her2 \text{ AND } EpCAM \text{ NOT } EGFR]$  logic mechanism. The Decoy acts as a sponge to sequester the Key, thereby preventing Cage activation. (E)  $CL_{C_H K_{Ep} D_E}$  was used to recruit Bcl2-AF594. Compared to the simple  $CL_{C_H K_{Ep}}$  AND gate (left), recruitment of Decoy to EGFR-expressing cells reduced activation to near background levels. For all panels, population 1 was  $[K562/EpCAM^{lo}, K562/EGFR/EpCAM^{lo}, K562/EpCAM^{lo}/Her2, \text{ and } K562/EGFR/EpCAM^{lo}/Her2]$ , and population 2 was  $[K562/EpCAM^{lo}, K562/EGFR/EpCAM^{lo}, K562/EpCAM^{hi}/Her2, \text{ and } K562/EGFR/EpCAM^{hi}/Her2]$ . Error bars represent SEM of 6 independent replicates for K562 and K562/EGFR and 3 independent replicates for all others. Statistics are reported in table S4.



**Fig. 4. Co-LOCKR directs CAR T cell specificity using 2- and 3-input logic operations.** (A, D, and G) Mean IFN- $\gamma$  concentration in cell supernatants 24 hours after co-culture of Cage, Key, and K562 cells with CAR T cells. Marker expression for each cell line and identity of the Cage and Key targeting domains are indicated below each bar plot. Red highlighting indicates the expected magnitude of signal based on the target cell's relative antigen expression. Error bars represent SEM of  $n = 4$  (A) or 3 [(D) and (G)] healthy T cell donors. AND/NOT logic is demonstrated with EpCAM<sup>lo</sup> target K562 cells because T cell effector function was leaky for EpCAM<sup>hi</sup> target cells (see fig. S15A). (B, E, and H) CAR T cell proliferation in response to [*Her2 AND EpCAM*] (B), [*Her2 AND EGFR OR EpCAM*] (E), or [*Her2 AND EpCAM NOT EGFR*] (H) logic. Bar plots are the percent of T cells that have undergone at least one cell division by 72 hours after co-culture of CAR T cells, Cage, Key, and target K562 cells. Histograms show flow cytometric analysis of CFSE dye dilution gated on CD8<sup>+</sup> lymphocytes. The data are representative of  $n = 3$  biological replicates with healthy T cell donors. (C, F, and I) CAR T cell cytotoxicity against mixed populations of target Raji cells expressing combinations of Her2, EpCAM, and EGFR. Line graphs show mean frequency of Raji target cells after 0 or 48 hours of co-culture with CAR T cells.  $n = 4$  [(C) and (F)] or 3 (I) healthy donors. Arrows indicate cell lines targeted by Co-LOCKR.

## Designed protein logic to target cells with precise combinations of surface antigens

Marc J. Lajoie, Scott E. Boyken, Alexander I. Salter, Jilliane Bruffey, Anusha Rajan, Robert A. Langan, Audrey Olshefsky, Vishaka Muhunthan, Matthew J. Bick, Mesfin Gewe, Alfredo Quijano-Rubio, JayLee Johnson, Garreck Lenz, Alisha Nguyen, Suzie Pun, Colin E. Correnti, Stanley R. Riddell and David Baker

published online August 20, 2020

### ARTICLE TOOLS

<http://science.sciencemag.org/content/early/2020/08/19/science.aba6527>

### SUPPLEMENTARY MATERIALS

<http://science.sciencemag.org/content/suppl/2020/08/19/science.aba6527.DC1>

### REFERENCES

This article cites 33 articles, 7 of which you can access for free  
<http://science.sciencemag.org/content/early/2020/08/19/science.aba6527#BIBL>

### PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

---

*Science* (print ISSN 0036-8075; online ISSN 1095-9203) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science* is a registered trademark of AAAS.

Copyright © 2020, American Association for the Advancement of Science